Subscribe To

Price Alert Latest News Economic Calendar News

PODD / Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Lauren Budden - Interim Chief Financial Officer & Treasurer Conference Call Participants Stephanie Piazzola - Bank of America Jeff Johnson - Baird Matt Taylor - Jefferies Margaret Kaczor - William Blair Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Steven Lichtman - Oppenheimer Chris Pasquale - Nephron Marie Thibault - BTIG Josh Jennings - TD Cowen Danielle Antalffy - UBS Matt Miksic - Barclays Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. Read More

Demo Live Account See Partner Details

Content Topics

Insulet

Corporation

PODD

2023

Earnings

Call

Transcript

podd

Stock

Posted: Nov 2 2023, 22:10

Author Name: Seeking Alpha

PODD News

By Invezz
November 3, 2023

Insulet (PODD) stock up 14% on positive earnings and growth forecast

Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company'

By Barrons
November 3, 2023

Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.

The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier.

By Market Watch
November 3, 2023

Insulet shares rebound after results top estimates

Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat

By Seeking Alpha
November 2, 2023

Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President,

By Zacks Investment Research
November 2, 2023

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be

By Seeking Alpha
October 30, 2023

Insulet Corporation: Still No Bargain

Today, we take a look at Insulet Corporation, a mid-cap medical device concern. The company is focused on developing and marketing insulin delivery sy

By Zacks Investment Research
October 25, 2023

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

By Zacks Investment Research
October 17, 2023

Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measu

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.